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ABSTRACT 
 
USE OF INDUCED PLURIPOTENT STEM CELL MODELS TO ELUCIDATE RETINAL 
DISEASE PATHOGENESIS AND TO DEVELOP GENE-BASED THERAPIES 
Thu Thi Duong 
Jean Bennett  
Choroideremia (CHM) is a rare monogenic, X-linked recessive inherited retinal 
degenerative disease caused by mutations in the Rab Escort Protein-1 (REP1) encoding 
CHM gene. CHM is characterized by childhood-onset night blindness (nyctalopia), 
progressive peripheral vision loss due to the degeneration of neural retina, RPE and 
choroid in a peripheral-to-central fashion. Most of CHM mutations are loss-of-function 
mutations leading to the complete lacking of REP1 protein.  However, the primary retinal 
cell type leading to CHM and molecular mechanism remains unknown in addition to the 
fact of lacking proper disease models. In this study, we explored the utility of induced 
pluripotent stem cell-derived models of retinal pigment epithelium (iPSC-RPE) to study 
disease pathogenesis and a potential gene-based intervention in four different genetically 
distinct forms of CHM. A number of abnormal cell biologic, biochemical, and physiologic 
functions were identified in the CHM patient cells. Transduction efficiency testing using 11 
recombinant adeno-associated virus (AAV) serotype 1-9, 7m8 and 8b showed a 
differential cell tropism on iPSC and iPSC-derived RPE. We identified AAV7m8 to be 
optimal for both delivering transgenes to iPSC-RPEs as well as to appropriate target cells 
(RPE cells and rod photoreceptors) in the primate retina. To establish the proof of concept 
of AAV7m8 mediated CHM gene therapy, we developed a AAV7m8.hCHM viral vector, 
which delivers the human CHM cDNA under control of CMV-enhanced chicken β-actin 
promoter (CβA). Delivery of AAV7m8.CMV.CbA.hCHM to CHM iPSC-RPEs restored 
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protein prenylation, trafficking and phagocytosis defects. The results confirm that AAV-
mediated delivery of the REP1-encoding gene can rescue defects in CHM iPSC-RPE 
regardless of the type of disease-causing mutation. The results also extend our 
understanding of mechanisms involved in the pathophysiology of choroideremia. 
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CHAPTER 1 - INTRODUCTION 
RETINA AND RETINAL DISEASES 
Retina: structure, function and its diseases 
The retina is located in the posterior chamber of the eye and is comprised of 
multiple layers of cells functioning to gather light photons, turning them into neuronal 
signals, then transmitting the signals to the visual cortex of the brain to create our vision. 
The stratified neural retina contains, photoreceptor, amacrine, bipolar, horizontal, 
ganglion, and Müller cells, and the neural retina is anterior and adjacent to the retinal 
pigment epithelium (RPE) cell monolayer. Rod photoreceptors are responsible for dim light 
vision whereas cone photoreceptors, including S-cones, M-cones and L-cones, are 
sensitive to short-wavelength, medium-wavelength and long-wavelength light, 
respectively and are thus responsible for color vision. In humans or non-human primates, 
the macular region, in the center of the retina, has a foveal region which is concentrated 
with cone photoreceptors. This structure relays visual acuity. Retinal pigment epithelium 
resides adjacent  to the photoreceptor layers and plays a significant role in visual function 
and photoreceptor maintenance including: 1) light absorption; 2) reisomerization of all-
trans-retinal into 11-cis-retinal for the visual cycle; 3) transport of nutrients, ions, and water 
between photoreceptors and the choriocapillaris; 4) phagocytosis of photoreceptor outer 
segment for their continuous regeneration; and 5) secretion of trophic factors for the 
integrity of the retina and choriocapillaris (Simó et al., 2010). 
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There are many different non-syndromic and syndromic retinal diseases leading 
to irreversible blindness. They can be either dominant, recessive or X-linked disease, for 
example mutations in RPE65 which has an important role in reisomerization of all-trans-
retinal into 11-cis-retinal on retinoid cycle, can cause Leber Congenital Amaurosis 2 
(LCA2) (Cai et al., 2009). In another example, loss of function mutations in the CHM gene 
located on the X chromosome can cause Choroideremia (M. Preising and Ayuso, 2004). 
In terms of inherited retinal degeneration, there are more than 200 causative genes 
currently identified (Siemiatkowska et al., 2014). Mutations in any of those genes can alter 
the normal function of the retina at the molecular to physical level, causing degeneration 
of photoreceptors or RPE.  
Models to study retinal degenerative pathogenesis 
 To recapitulate human retinal diseases, there are several available model systems 
for study. Zebrafish provide an excellent model for studying ocular development because 
they are phylogenetically similar to human (70% of human genes are found in zebrafish), 
easy to genetically manipulation, they propagate regularly due to a short life cycle, their 
transparent embryos provide a useful tool for imaging and protein tracking during 
development, and maintenance requirements for zebrafish are minimal (Ail and Perron, 
2017; Link and Collery, 2015). Murine models are very popular for studies of human retinal 
diseases and development because of the similarity in anatomy and physiology. The 
growing toolbox for genetic and epigenetic modifications makes conditional and knockout 
mice very accessible for studies of various cellular and molecular pathways associated 
with pathogenesis of the disease. For ophthalmologic studies, the accessibility of the eye 
for non-invasive studies such as analyses of cellular structure and topography using 
optical coherence tomography (OCT), fundus imaging, and analyses of retinal function 
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using electroretinograms (ERGs) make animal models great resources for investigation 
(Veleri et al., 2015). Due to differences in the shorter life span of mice (1 years old mice = 
30 years old human in term of development), characterization of disease phenotypes and 
study of developmental biology can be expedited in murine models (Veleri et al., 2015).  
A challenge for murine models is that mice are nocturnal. They have an enrichment of rod 
(compared to cone) photoreceptors (unlike human) and do not have macula, a region 
responsible for color vision and visual acuity. Hence, in some diseases especially macular 
degeneration, murine models are not ideal. In many instances, the murine model does not 
recapitulate the human disease; therefore, providing a knockout or conditional genetic 
manipulation is not always useful. Non-human primate (NHP) models are the closest in 
term of genetic and functional similarity to humans and the presence of a macula is a 
major advantage for translational studies (Mustari, 2017). However, there are multiple 
factors making NHPs challenging model to study, e.g. the limited number of animals that 
can be studied, the ethical issues, the difficulties of genetic modification, the lack of 
disease models in NHPs, and the high expense of maintaining the large animal models 
(Mustari, 2017). Since the discovery of embryonic stem cells (ESC) and induced 
pluripotent stem cells (iPSC), patient derived cellular models harboring precise mutations 
of each patient facilitate scientific elucidation of disease pathogenesis. Pluripotent stem 
cells provide a tool to study the early development of the retina as they create a means 
for investigating all three germ layers; endoderm, mesoderm, and ectodermal tissues. 
Recently, a significant amount of effort has been put into developing highly efficient and 
sophisticated strategies to generate retinal cell subtypes in two-dimensional or three-
dimensional cultures (Nakano et al., 2012; David A. Parfitt et al., 2016; Sonoda et al., 
2009; Zhong et al., 2014). Given the capacity of iPSCs to recapitulate embryonic 
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development, these cells have been able to replace embryonic stem cells eliminating the 
ethical issues with human ESCs.   
 
CHOROIDEREMIA  
 
Choroideremia (CHM) is an X-linked recessive chorioretinal dystrophy 
characterized by the degeneration of retinal photoreceptor cells, retinal pigment epithelium 
(RPE) and choroid. The onset of clinical symptoms in CHM, is typically observed within 
the first or second decade of life. Early symptoms observed are poor night vision and a 
progressive loss of peripheral vision. As the disease progresses, there is a loss of central 
vision leading to eventual complete blindness. The latter can be observed by the fifth 
decade of life. (Aleman et al., 2017; Sanchez-Alcudia et al., 2016) The disease typically 
affects only males, while females are carriers of the disease. The prevalence of CHM is 
about 1:50,000, hence it is considered a rare disease. Disease mechanisms are believed 
to be molecularly and biochemically explained by the lack of Rab Escort Protein 1 (REP1) 
function due to loss-of-function mutations in the REP1-encoding CHM gene. This results 
in loss of posttranslational lipid modification of ras-related GTPases, or Rab proteins 
(prenylation of Rab proteins). The defect in prenylation disrupts intracellular trafficking of 
vesicles, motility and fusion of organelles in cells, specifically retinal cells (RPE, 
Photoreceptors). However, the primary cell type(s) causing the degeneration is still not 
clearly identified. Currently, there are no established treatments for CHM; however, there 
are two early phase AAV mediated gene therapy clinical trials for CHM that were initiated 
several years ago and are on-going (Nightstar Therapeutics, 2018a; Spark Therapeutics, 
2018) and plans for a phase 3 trial (Nightstar Therapeutics, 2018b). 
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CHM pathophysiology  
 
CHM is an X-linked disease, so it affects hemizygous males. Patients with 
choroideremia experience night blindness in the first or second decade of life, followed by 
progressive peripheral vision loss. This leads to tunnel vision which ultimately encroaches 
on the fovea and often leads to complete blindness in the fourth to fifth decades of life. 
Fovea region which determines central vision is the last area that was observed to be 
affected in CHM. Fundus images show a progressive atrophy of the choriocapillaris and 
RPE which expands in a peripheral to central fashion (M. Preising and Ayuso, 2004). This 
pattern suggests a secondary degeneration of photoreceptors due to primary and 
progressive RPE atrophy. Histopathology studies on a deceased eye from a 30-year-old 
male with choroideremia caused by a nonsense mutation, revealed an independent 
degeneration of all affected cell types affected in CHM, including choriocapillaris, RPE, 
and photoreceptors (MacDonald et al., 2009). The clinical profile at any given age and 
between the two eyes of affected subjects with choroideremia can be variable suggesting 
that, although CHM is a single gene defect, other factors may play a role in moderating 
the final disease phenotype. The heterozygous carrier females do not develop a visual 
impairment, but may have signs of patchy chorioretinal degeneration due to random X-
chromosome inactivation (Heckenlively and Bird, 1988).  
 
CHM mutations 
 
The CHM gene (OMIM:300390) is comprised of 15 exons and spans over 180 kb 
of Xq21.2. The coding sequence of CHM is 1.9 kb and the gene encodes a 653 amino 
acid protein, REP-1. There are more than 300 mutation variants that have been identified 
in the CHM gene in individuals with choroideremia and these mutations can affect any 
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region of the gene. These mutations include nonsense, missense mutations, splicing 
defects, small and large insertions and deletions (Simunovic et al., 2016). There is a small 
group of CHM patients in whom mutations were not identified. Overall, the majority of 
causative mutations of CHM are loss-of-function mutations leading to the absence of 
REP1 protein physically and functionally. In addition, there are a couple of missense 
mutations in CHM that have been reported. A novel CHM missense variant (c.1520A>G; 
p.H507R) was discovered to be associated with the disease in Italian CHM patients 
(Esposito et al., 2011). This missense mutation does not cause any difference in mRNA 
and DNA level, but creates a lesser amount of functional REP1 protein than found in 
unaffected individuals. In addition, the REP1 protein in such patients is unable to associate 
with RabGGTase for a normal prenylation cycle (Esposito et al., 2011).  Another missense 
variant in CHM is c. 1679T>C (p. L550P) which may cause the instability of native folded 
REP1 protein due to a mutation-caused lack of a hydrogen bond between the two beta 
strands (Sergeev et al., 2009). CHM mutations were observed to be located in both coding 
and non-coding regions of CHM. A recent publication investigated the potential for variants 
in the CHM promoter region (c.-98: C>A and C>T), to segregate with the disease 
(Radziwon et al., 2017). An effort to study the correlation of genotype and phenotype in a 
cohort of 74 CHM patients with mutations ranging from insertions, to deletions, splicing 
defects, and single point mutations in which majority were null mutations indicated no clear 
relationship in terms of the effects of the mutations on visual acuity, visual field, residual 
retina area, age of onset (Simunovic et al., 2016).  
Function of REP1 protein 
 
The REP-1 protein is ubiquitously expressed in the body. It plays an important role 
in the prenyl (geranylgeranyl) post-translational modification of Rab GTPases (Rab), 
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members of the Ras superfamily of monomeric G proteins. A vast variety of Rab proteins 
has been identified so far. All these Rabs, when integrated in membranes, are involved in 
protein trafficking, docking and membrane tethering. Before integration of Rabs into 
membranes, they must be post-translationally modified through the addition of two prenyl 
groups to 1-2 cysteines located near the C-terminus of the Rab protein (Pylypenko et al., 
2003; Seabra et al., 1995, 1992; Strunnikova et al., 2009).  This geranylgeranyl post-
translational modification is called prenylation. In the cytosol, REP1 will present newly 
synthesized, unprenylated hydrophilic Rab proteins to a catalytic Rab 
geranylgeranyltransferase (GGTase) in order to add geranylgeranyl group into Cysteine 
residues on the C-terminus. Then the prenylated Rabs are escorted to their specific 
destination membrane (Pylypenko et al., 2003), a fundamental process for intracellular 
vesicular transport in endocytic and exocytic pathways.  
An accumulation of unprenylated Rab proteins in the cytosol is an indication of the 
lack of REP1 characterizing CHM patients. Even though REP1 protein is observed to be 
completely absent in CHM patients, the disease phenotype is specific to the ocular tissue, 
indicating the retina-specific role of REP1. The lack of other symptoms in patients with 
choroideremia is due to compensation by a redundant autosomal homologue of CHM, 
CHML, choroideremia-like protein (REP2), is located on chromosome 1q42 (Cremers et 
al., 1994). REP2 has an additional three amino acids and is encoded by just one single 
exon. However, it is 75% identical to REP1. Due to these similarities, REP2 compensates 
for the function of REP1 in non-ocular tissues. The affinity of REP1 with Rabs is higher 
compared to REP2 (Köhnke et al., 2013; Rak et al., 2004).  
The addition of a prenyl group will tether the Rab proteins to the membrane 
associated with the trafficking of related proteins (M. N. Preising and Ayuso, 2004). There 
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are more than 70 types of Rab proteins. Choroideremia could be due to a deficiency of 
prenylation in multiple Rab proteins, for example, Rab27a, Rab6, and/or Rab8. In the 
photoreceptor, the intracellular trafficking of proteins from the inner segment to the outer 
segment, rhodopsin for example, occurs via the budding of vesicles from the Golgi 
apparatus to the connecting cilium. This is regulated by Rab8 and Rab6 (Deretic, 1998). 
In the RPE, intracellular trafficking by Rab27a protein in combination with myosin VIIA 
controls the phagocytosis and degradation of photoreceptor outer segments via the 
transport of the phagosome (Gibbs et al., 2003). In retinal tissue, loss of REP1 can affect 
the trafficking of opsin from the cell body to outer segment regions, or the migration of 
melanosomes to the apical region, as well as the rate of phagocytosis of photoreceptor 
outer segments by the RPE.  
Recent studies of a cohort of 9 patients with CHM mutations revealed systemic 
findings such as prominent crystals in lymphocytes and significant fatty acid abnormalities 
(Zhang et al., 2015a) suggesting that molecular mechanism of CHM is may extend to other 
cell types.  
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Figure 1. A schematic of the cellular function of Rab escort protein (REP1). 
REP1 presents newly synthesized, unprenylated Rabs to a catalytic Rab 
geranylgeranyltransferase (GGTase) subunit in order to add one or more hydrophobic 
prenyl groups (geranylgeranyl, GG shown here) to carboxy-terminal cysteine residues 
(a process called prenylation). Prenylated Rabs have as their characteristics, the ability 
to target particular membranes in the Golgi apparatus (GA) and of diverse cellular 
vesicles (Vesicle, represents various cellular vesicles, e.g., lysosomes or transport 
vesicles) (Alun R. Barnard, Markus Groppe, 2015). 
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Disease models 
 
The pathophysiological mechanism of CHM is complex and not yet clearly known. 
RPE and photoreceptors have a tight inter-connected relationship which suggests that if 
either cell layer degenerates, that will lead to a secondary degeneration of the other. 
Identification of the primary cell type causing the disease would pave the way in 
developing gene augmentation therapy targeting the appropriate affected cells. To 
understand more about the pathophysiology of the disease, various animal models were 
developed.  
Zebrafish CHM model 
In 2007, Krock et al. reported a degeneration of RPE and photoreceptors in 4.5 
days post fertilization chm nonsense mutant fish. Studies of the mosaic model suggested 
that defective RPE cells failed to phagocytize outer segments of photoreceptors thereby 
leading to secondary degeneration of the photoreceptors (Krock et al., 2007). In fact, 
disease in the chm (-/-) zebrafish manifests as an extremely severe systemic illness 
resulting in early lethality at day 5 to day 6 post fertilization (Moosajee et al., 2009). This 
severe lethality is explained by the lack of redundancy of other isoforms of REP1 (e.g. 
REP2 in mammalian) in this common non-mammalian vertebrate model organism. This 
severe phenotype limits the application of zebrafish model in studying human CHM 
disease.  
 
Murine CHM model 
Chm knock-out in mice is embryonically lethal. Complete loss of REP1 in 
hemizygous males and heterozygous females caused embryonic death when the gene 
was transmitted from heterozygous females (Van den Hurk et al., 1997). This might 
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indicate the difference in function of REP1 in mice compared to humans. The cell type 
specific conditional knockout mouse model has been created to study the independent 
role(s) of photoreceptors and RPE relative to the disease manifestation (Tolmachova et 
al., 2010). Loss of REP1 in photoreceptors of these mice resulted in a slowly progressive 
photoreceptors degeneration while the RPE layer maintains to be healthy with normal 
pigmentation and melanosome distribution. Loss of REP1 in RPE cells only was not 
observed to alter the integrity of photoreceptors layer, but shown to affect the pigmentation 
of RPE in some areas and the distribution of melanosomes in RPE. Further evaluation of 
the RPE specific REP1 ablation in mice showed a decrease of melanosomes in the apical 
side and a delay in phagosome degradation (Silène T. Wavre-Shapton et al., 2013). In 
these mice, melanosomes were observed to be localized in the cell body, leading to 
decreased melanosomes in the apical area of the RPE. In the mouse model where REP1 
was absent in both RPE and photoreceptors, acceleration of photoreceptors degeneration 
was reported only in young mice. This study revealed that either photoreceptors or RPE 
can be the primary cell type that leads in CHM disease. However, none of these models 
were successful in mimicking a human CHM disease phenotype. The major hurdles in 
developing any therapeutic strategies for monogenic disease are the failure to establish 
the molecular mechanism underlying the disease progression or the lack of suitable 
animal model to test the therapy. In CHM, the challenge is that the genetically modified 
animal model does not closely resemble the functional and morphologic characteristics of 
the human CHM disease with complete accuracy. Moreover, the engineered models are 
not readily available. Therefore, it is important to focus studies on developing in vitro cell 
based methods to understand the pathophysiology of the disease and to test the 
therapeutic approach. For these reasons, human derived cell types from induced 
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pluripotent stem cells are considered as promising models to study this CHM 
pathogenesis. 
 
In vitro cellular models 
Development of therapeutic interventions in certain retinal degenerative diseases 
is hampered by the lack of relevant models of the diseases. As the current research on 
human subjects, particularly for therapeutic interventions for retinal diseases, is limited by 
ethical guidelines, establishment of surrogate models that accurately recapitulate disease 
phenotypes is necessary. These cell-based models could enable the efficient translation 
of basic research so that it could ultimately then be applied in the clinical setting. Potential 
in vitro models would include primary retinal photoreceptors or RPE cells that are specific 
to patients. But obtaining these cells as a biopsy from living human retina would be harmful 
to the patient. The recent advancement of induced pluripotent stem cell (iPSC) and 
embryonic stem cell (ESC)-derived cells could technically establish an in vitro model 
system to study CHM. 
As shown in CHM murine model, photoreceptors and RPE have an independent 
effect on CHM disease pathogenesis. Taking advantage of induced pluripotent stem cell 
technology, patient derived cellular model may serve as personalized models to explore 
the disease mechanism. In the retina, photoreceptors directly connect with RPE and get 
support from RPE to perform their visual function in term of structure integrity, trophic 
factors secretion, nutrient exchange, visual cycle, outer segment phagocytosis (Sparrow 
et al., 2010; Strauss, 2005). 
The photoreceptor cell is not an easy cell type to culture for research purpose. 
Scientific evidence shows that photoreceptors quickly lose their structural integrity when 
cultured. Studies using an in vitro co-culturing system with RPE cells were carried out to 
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try to overcome this, but still, culturing of photoreceptors was not successful. Generating 
3D retinal eyecups is a recent advancement aiming to develop a structure resembling the 
mature retinal tissue (Zhong et al., 2014) with an achievement of a few outer segments in 
those optic vesicles. However, the ability to generate fully mature photoreceptors still has 
a long way to go and it is a real challenge (Zhong et al., 2014).   
Compared to the culture of photoreceptors, culture of retinal pigment epithelium 
(RPE) in vitro has been shown to result in maintenance of the RPE fundamental 
characteristics. Fetal RPE was cultured and developed a thin, confluent cell layer with 
pigmented hexagon morphology with the expression of all RPE markers as measured at 
transcriptional and translational levels (the early eye field development marker, PAX6; the 
RPE-specific transcription factors MITF and OTX2; the tight junction marker, ZO-1, N-
cadherin; the secreted, PEDF, VEGF; the membrane-associated proteins, BEST1; the 
visual cycle proteins, RPE65, LRAT, CRALBP; the pre-melanosome protein (PMEL17) 
(Sonoda et al., 2009; Zhang et al., 2012). RPE was cultured in apical or basal surfaces, 
melanosome transport to apical side, as the establishment of tight junction between cells 
as measured by high transepithelial resistance (TER) (Sonoda et al., 2009). Patient 
derived RPE from human embryonic stem cells or induced pluripotent stem cells has been 
generated over the last decade to serve the purpose of modeling in vivo RPE. Improving 
from a spontaneous differentiation protocol to a direct differentiation using a combination 
of retinal inducing factors (IGF1, Noggin, Dkk1, and bFGF) and other factors 
(nicotinamide, Activin A, SU5402, and VIP), efficiency of in vitro RPE differentiation 
increased from a small portion of cells to 80% population that has Pmel17 expression (pre-
melanosome protein) (Buchholz et al., 2009; Uchholz et al., 2013).  
iPSC and iPSC derived RPE were used as tools to study CHM disease 
mechanisms by two different groups (Cereso et al., 2014; Vasireddy et al., 2013). iPS cells 
14 
 
generated by CHM patients showed the lack of function of REP1 proteins. Both studies 
delivered the functional REP1 using adeno-associated virus and tested the ability to 
restore REP1 function in personalized in vitro models of CHM.  
Gene augmentation therapy  
 
Since the molecular mechanism behind choroideremia is the loss of functional 
REP1, delivering functional REP1 protein to the retina could protect the retina from 
degenerative changes. Targeting the monogenic disease caused by mutations is usually 
based on gene correction or gene augmentation. Rather than correcting the nonfunctional 
gene, gene augmentation therapy serves as a superior strategy, where a functional copy 
of the deficient gene will be delivered to the cells that are affected by loss of the specific 
gene. Gene augmentation was reported to work well for recessive diseases where there 
is a complete lack of functional protein.  Delivery of functional genes/proteins can be 
achieved by both non-viral and viral mediated approach. Non-viral mediated gene delivery 
is focused on delivering the functional gene without using any viral vectors. The advantage 
of using this strategy is a) less immunological response due to the viral capsids; 2) the 
ability to package larger genes.  Even though this strategy is less toxic, several challenges 
including low efficacy and transient expression still need to be addressed.  
On the other hand, viral mediated gene augmentation therapy uses recombinant 
viral vectors to deliver transgenes. A variety of recombinant viral vectors, like retrovirus, 
lentivirus, adenovirus, is available that can deliver the transgene to specific cell types. Due 
to the safety and efficacy profile of recombinant adeno-associated virus (AAV) in animals 
and humans, this viral vector has become a useful tool in several degenerative diseases, 
including retinal degeneration. Recombinant adeno-associated viruses are currently the 
most favorable viral vectors for gene augmentation therapy due to their low 
15 
 
immunogenicity, toxicity; lack of genome integration; and the ability to transduce both 
dividing and quiescent cells in a stable fashion. 
 
Adeno-associated virus (AAV) 
 
Adeno-associated virus has opened a new chapter for gene therapy after a long 
challenging time dealing with immunogenicity of adenovirus or lentivirus. Adeno-
associated virus (AAV) is a small, non-enveloped, non-pathogenic dependoparvovirus 
which was discovered in 1965 as a co-infecting contaminant in infections of the common 
cold virus, Adenovirus (Atchison et al., 1965). The AAV genome comprises of 4.7kb single 
strand DNA encoding for Rep protein (for replication and packaging) and Cap protein (for 
capsid structure), flanked by two hairpin structure ITRs (inverted terminal repeat) (Vance 
et al., 2015). To perform its infection, AAV requires a helper virus, for example, adenovirus 
or herpesvirus. Recombinant AAV is created by removing the Rep and Cap gene and 
replacing the expression cassette containing the gene of interest. The size of a transgene 
to fit in AAV genome is around 4.7 kb. AAV vector has become a favorite vector to use in 
gene therapy thanks to its safety (no toxicity, no-known immunological response on 
human, no integration in host genome) and its efficient transduction efficiency in vitro and 
in vivo. There are >12 different serotypes that have been used in animal and human 
studies in a total of more than 100 natural variants of AAV. All of the rAAV vector was 
generated in research using the ITRs of AAV serotype 2’s genome and then packaged in 
other AAV’s Cap and Rep sequence provided in trans. Capsid sequence from AAV 1-9 
has more than 80% homology except for AAV4 and AAV5 have the most divergent 
sequence. The difference is mostly located in the looped-out domains which are exposed 
to the surface of the capsid (Vance et al., 2015). Even a six amino acid difference between 
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AAV1 and AAV6 could dictate a different binding receptor of each AAV. The AAV7m8 
serotype is a genetic variant of AAV2 containing 7 peptides (LGETTRP) disrupting its 
binding to heparan sulfate proteoglycan (HSPG) receptor (Chen, 2015; Dalkara and 
Byrne, 2013). It was isolated and characterized after an in vivo-directed capsid evolution 
by injecting a mixture of three libraries intravitreally into the mouse eyes and collecting the 
capsid libraries of AAV particles that could access to photoreceptors layer (Chen, 2015; 
Dalkara and Byrne, 2013). AAV8b was generated from in vivo directed evolution via 
inserting a random region in between the residues from amino acids 585 to 593 of the 
AAV8 capsid to target ON-bipolar cells (Cronin et al., 2014).   
The tropism of each AAV serotype on each cell type/tissue is variable due to a 
complex molecular mechanism of AAV infection, such as interaction of AAV capsid with 
different receptors on cellular surface, endocytosis of AAV particles, the amount of AAV 
particles access to the nucleus. AAV2 requires heparin sulfate proteoglycan (HSPG), 
AAV9 needs N-terminal galactose, and AAV1, 4, 5, and 6 bind specific N- or O linked sialic 
acid moieties (Kern et al., 2003; Murlidharan et al., 2014). A genetic screening to detect 
the most significant enrichment of KIAA0319L gene during AAV2 infection suggested it 
encodes for a so called universal AAV receptor (AAVR) (Pillay et al., 2016). In addition, 
the expression of AAVR in cell lines specific AAVR knockout rescued the infection in 
multiple AAV serotypes (Pillay et al., 2016). However, the role of AAVR in every AAV 
serotypes infection pathway as well as whether or not AAVR is efficiently a universal 
receptor for all AAV serotypes need to further investigated (Summerford and Samulski, 
2016). With the complexity of AAV infection and the diversity of AAV serotypes, one direct 
way to understand the expression of transgene using AAV is via screening the specific 
transduction efficiency of AAV serotypes on in vitro cellular models and/or animal model.  
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AAV mediated gene therapy: clinical trials  
 
The first AAV mediated gene therapy product that was approved by the European 
Commission in 2012 was Glybera (alipogene tiparvovec). This AAV carries the human 
lipoprotein lipase gene which is delivered to treat lipoprotein lipase deficiency (Moran, 
2012). 
In the US, there have been recent great strides in gene therapy, with three gene 
therapy products approved by the US Food and Drug Administration in 2017. There are 
the first gene therapy products approved in the USA. The first is Kymriah 
(tisagenlecleucel), which is an ex vivo therapy for certain pediatric and young adult 
patients with a form of acute lymphoblastic leukemia (ALL). The second is Yescarta, a 
chimeric antigen receptor (CAR) T cell therapy designed for ex vivo treatment of certain 
types of non-Hodgkin lymphoma. And the third, is the first gene therapy in the USA 
designed to be injected directly into the diseased target tissue (the retina), Voretigene 
Neparvovec-rzyl. This is also the first gene therapy product approved to treat a blinding 
disease. 
Luxterna is a recombinant AAV serotype 2 (AAV2) vector carrying a normal copy 
of the RPE65 gene, a gene which when mutated causes an autosomal recessive 
congenital form of severe blindness, Leber congenital amaurocis (LCA). The RPE65 gene 
is normally expressed in RPE (Maguire et al., 2009, 2008; Russell et al., 2017). The 
success of Luxterna, which has reversed blindness safely and stably and bilaterally in the 
majority of eyes of the Phase 3 clinical trial subjects, paves for way for development of 
gene therapies for other monogenic progressive diseases affecting the retina, including 
choroideremia. Since cells in the retina do not divide after birth, the reagent can be 
delivered once without concern about the reagent being diluted out due to cell division. 
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There are several reasons why CHM is one of the lead contenders for additional 
success in developing a gene therapy product. First, almost all CHM mutations result is 
complete loss of functional REP1, suggesting that adding exogenous REP1 (through gene 
delivery) would rescue the disease phenotype. Second, the progression is slow so that 
time windows for the therapeutics is long. Third, the coding sequence of CHM is less than 
1.5 kb allowing a comfortable fit in the AAV vector’s cargo hold. Finally, the subretinal 
injection method is available to target directly and efficiently the cells in the retinal area 
like RPE or photoreceptors which were affected cell types in CHM (Peng et al., 2017).  
The first gene augmentation clinical trial for choroideremia using AAV2 was 
initiated in the United Kingdom in 2011 (ClinicalTrials.gov Identifier: NCT01461213) 
(MacLaren et al., 2014). In this study, 6 male patients (age 35 to 63 years) were 
subretinally injected with 0.6 – 1E10 AAV2.REP1 vector genomes. The best corrected 
visual acuity in two patients at advanced stage of disease increased 21 and 11 letters 
compared to the untreated eye, and this improvement was maintained until at least 3.5 
years after treatment. Three other patients did not show a significant change and one 
patient decreased in visual acuity. The microperimetry to measure retina sensitivity 
increased 2.3 dB on average. The safety profile is excellent with no adverse event for the 
eyes and no immune response (Edwards et al., 2016; MacLaren et al., 2014). With this 
initiation, additional sites initiated gene augmentation clinical trials for choroideremia using 
Nightstar as a sponsor. Recently, Nightstar announced initiation of a Phase 3 
(registrational) trial for choroideremia (Nightstar Therapeutics, 2018b).  
Meanwhile, in the U.S.A., Spark Therapeutics initiated a Phase 1/2 trial to evaluate 
the safety and preliminary efficacy of SPK-7001 on choroideremia patients (Spark 
Therapeutics, 2018). Given the high degree of safety of AAV2 after subretinal injection (as 
demonstrated in the RPE65 clinical trials and, subsequently, in the Nightstar 
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choroideremia trial), this was also chosen to be the gene delivery vector in Spark’s multi-
center CHM clinical trial. The latter trial was initiated in 2015 using a vector for which 
efficacy had been demonstrated in vitro, in iPSCs derived from individuals with 
choroideremia. So far, AAV2 has been relatively benign after subretinal injection in 
choroideremia, even though the region targeted is a region which is highly vulnerable to 
mechanical stress due to the fact that it is a single cell layer: the fovea. One outcome 
desired in these studies is that the intervention will allow the cells in the retina to persist 
for longer, and thus to provide vision for longer. Because the disease is slowly progressive, 
it may take several years to determine whether this reagent confers any benefit.  
Meanwhile, additional studies aim to probe the utility of other recombinant AAV 
vectors that may have more desirable properties in terms of transduction of the RPE and 
photoreceptors. 
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2.1. Human pluripotent stem cells generated from CHM probands 
Primary peripheral blood mononuclear cells (PBMCs) were collected from four 
CHM probands carrying mutations in the CHM gene. The CHM gene mutations included 
1) CHM-1 (JB-415, c.1327_1328delAT), 2) CHM-2 (JB-500, exon 2-4 deletion), 3) CHM-
3 (JB-527, exon 2-4 deletion), and 4) CHM-4 (JB-588, Arg555STOP, AGA->TGA). 
Mutation validation was performed on patient derived iPSC gDNA using primers in Table 
1. All human protocols were approved by the institutional review board (IRB) at the 
University of Pennsylvania and each donor provided signed informed consent (IRB 
808828). PBMCs were expanded in SP34 media containing IL-3, IL-6, SCF, and FLT3 
plus penicillin/streptomycin and glutamine. Reprogramming of expanded PBMCs were 
performed as previously described (Maguire et al., 2015). Cells showing iPSC morphology 
were collected and expanded in iPSC medium (iPSC.CM; DMEM/F12 (50:50; Corning) 
containing 1 x glutamine (Life Technologies), 1 x penicillin/streptomycin (Life 
Technologies), 15% Knockout serum replacement (KSR) (Life Technologies), 1 x NEAA 
(Life Technologies),, 0.1 mM β-mercaptoethanol (2-ME) (Life Technologies), and 5 ng/mL 
of bFGF (R&D Systems) on 0.1% gelatin-coated dishes with irradiated mouse embryonic 
fibroblast (iMEFs). Cell lines were expanded and characterized for morphology, 
pluripotency gene expression (cMYC, DNMT3B, Nanog, OCT3/4), surface markers 
expression (SSEA3-488; Biolegend 1:100, SSEA4-647, Biolegend 1:100), Sendai 
transgene clearance, and all g-banding analyses were performed by Cell Line Genetics, 
Inc. CHM iPSCs were cultured on 1:100 matrigel-coated dishes in StemFlex media 
(Invitrogen) to perform germ layer specific analysis; mesodermal cultures (days 0-2: RPMI 
media plus 1 µM Chir99021, 5 ng/mL BMP4, and 50 ng/mL VEGF), days 3-7: serum free 
media (SFM) containing (5 ng/mL BMP4, 50 ng/mL VEGF, and 20 ng/mL bFGF), 
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Endodermal (days 0-2: RPMI media plus 2 µM Chir99021, 50 ng/mL Activin-A), days 3-7: 
SFM media containing (0.25 ng/mL BMP4, 10 ng/mL VEGF, 5 ng/mL bFGF, and 50 ng/mL 
Activin-A), Ectodermal (days 0-7: DMEM/F12 media containing 2% B27, 1% N2, 100 nM 
LDN193189, 10 mM SB431542, and 2 µM XAV939).  Cultures were collected after 7 days 
and analyzed for lineage-specific genes and compared to iPSC RNA. The primers for 
pluripotency and germ layer are provided in Table 2. The unaffected control iPSCs 
(JBWT2 (PBWT2), JBWT3 (PBWT3), JBWT4 (BMC)) were previously characterized and 
published (Mills et al., 2013; Sullivan et al., 2014). 
 
2.2. Retinal pigmented epithelium (RPE) differentiation 
iPSCs were cultured on 0.1% gelatin-coated plates containing iMEFs in 370C 5% 
O2 5% CO2 until initiation of RPE differentiation. Cell lines were placed in feeder 
independent growth conditions by passaging iPSC from iMEFs to matrigel-coated dishes 
using TrypLE (Life Technologies). Once placed on matrigel-coated dishes, cells were 
maintained in mTESR (Stem cell Technologies) medium until cells reached a confluence 
of 50-60%. At this confluence, cells were transferred to 370C 5% CO2 incubator and RPE 
induction was initiated. The base media for days 0-14 was DMEM/F12 plus 2% B27 
(ThermoFisher), 1% N2 (ThermoFisher), 1 x Penicillin/Streptomycin, and 1x Glutamax. On 
days 0-2 (48 h), cells were treated with Noggin (50 ng/mL), DKK1 (10 ng/mL), 
Nicotinamide (10 mM), and IGF-1 (10 ng/mL) feeding daily. On days 2-4 (48 h), cells were 
treated with Noggin (50 ng/mL), DKK1 (10 ng/mL), Nicotinamide (10 mM), IGF-1 (10 
ng/mL), bFGF2 (5 ng/mL). On days 4-6 (48 h), Activin-A (100 ng/mL), IGF-1 (10 ng/mL), 
and DKK1 (10 ng/mL). On days 6-14 (9 days), Activin-A (100 ng/mL), SU5402 (10 µM), 
and VIP (1 nM). On day 15, media was switched to RPE media DMEM/ Ham’s F12 (70:30), 
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2% B27, 1 x Glutamax, and 1 x Penicillin/Streptomycin. Cells were maintained in RPE 
media for 21 days. At day 35, cells were passaged using Accutase plus DNase1 using a 
two-step approach. Cells were initially treated for 20 min with Accutase + DNase1 to 
eliminate no-RPE cells, washed 2 x with PBS, and then treated with Accutase/DNase1 for 
20 min. Cells were detached using p1000 and centrifuged at 1500 rpm for 5 min. Cells 
were suspended in X-Vivo 10 media containing ROCK inhibitor, Thiazovivin (2 µM). All 
subsequent expansion of RPE included addition of Thiazovivin (2 µM), which allows for 
extended passaging of iPSC-RPEs.  
 
2.3. Transepithelial electrical resistance (TER) 
iPSCs were grown on fibronectin coated (5 µg/mL: 1.66 µg/filter) transwell filters 
for 3-4 weeks post-passaging to establish a monolayer RPE culture. TER of iPSC-RPE 
cultures was measured using a volt-ohm meter following manufacturer’s instructions 
(World Precision Instruments, Sarasota, FL). The TER was calculated by subtracting the 
background TER measurement from the fibronectin-coated transwell containing no cells 
from the TER recording of control or CHM iPSC-RPEs. Each iPSC-RPE cell line had a 
minimum of 9 transwells measured per individual and TER (Ω cm2) was measured weekly 
after reaching confluence and displaying a cobblestone appearance.  
2.4. Apical and basal secretion of VEGF and PEDF from RPEs 
Control and CHM iPSC-RPE monolayers on transwells with a TER > 250 Ω cm2 
were fed with X-Vivo 10 media in both the apical (500 µl) and basal (1 mL) chambers. 
After 24 h, media was collected separately from each chamber (minimum of 9 per 
individual) and subjected to ELISA assay for secreted proteins; VEGF (R&D systems) and 
PEDF (R&D systems) in accordance with manufacturer’s recommendations.  
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Basically, for VEGF ELISA, the VEGF primary antibodies were attached on the 
surface of the ELISA plate. VEGF protein standard at different dilutions as well as diluted 
supernatant from basal and apical chambers containing secreted VEGF from different 
lines of RPE cells were added into each well at triplicate. Human VEGF conjugated was 
added, incubated for 2 h and washed off. Substrate and stop solution was added in the 
final step. Color changes represents the amount of VEGF in the media. The optical density 
(OD) was measured using a microplate reader (Infinite M200Pro, Tecan) set to 450 nm 
and wavelength correction set to 540 nm. Standard curve was developed using the OD 
values of VEGF protein standard samples.  
For PEDF ELISA, human Serpin F1 capture antibody were diluted and coated on 
ELISA plate (Costar) for overnight at room temperature (RT). Capture antibody was 
washed and blocking reagent containing 5% BSA was added for 1 hour at RT. 100 µL of 
various diluted standards and samples were added to each well in triplicate and incubate 
for 2 hours at RT. Next, samples and standards were washed away and human Serpin F1 
detection antibody was added. Another wash step follows by addition of 100 µL 
Streptavidin-Horseradish Peroxidase (HRP). Then Streptavidine-HRP was washed away 
and substrate solution and stop solution were added accordingly. The optical density (OD) 
was measured using a microplate reader set to 450 nm and wavelength correction set to 
540 nm. Standard curve development and results generation were similar to VEGF ELISA 
assay. Values were adjusted for differences in volume from apical and basal chambers. 
 
2.5. RNA isolation, cDNA synthesis and qRT-PCR analysis 
Total RNA purification was carried out on iPSC and RPEs as directed in PureLinkTM 
RNA Micro Kit protocol (Invitrogen) including the optional on-column DNase step. RNA 
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was isolated from iPSC or RPEs and first strand synthesis was performed using TaqMan® 
Reverse Transcription Reagents. Protocol was followed as instructed by manufacturer, 
with each sample yielding a 20 µL reaction from 1 µg of RNA by using random hexamers 
as the primer type. cDNA was stored at -20 0C until needed for downstream analysis. For 
qRT-PCR, 10 ng of cDNA was mixed in a reaction containing 1 x Taqman Fast Universal 
PCR Master Mix (2x), 1 x TBP primer (VIC probes) and 1 x primers of specific target (FAM 
probes) and run in triplicate in a MicroAmpR Fast Optical 96-well reaction plate (Applied 
Biosystems) using quantitation-comparative CT (DDCT) set-up of 7500 Fast Real-Time 
PCR system machine (Applied Biosystems). The specific primers for MITF, BEST1, 
Pmel17, TYR, N-cadherin, TBP were described in Table 2.  
2.6. Immunofluorescence  
RPEs plated on 8-well chambers were coated with 1:100 matrigel and placed in 
37 0C incubator overnight. The next day media was removed and chamber slides with 
matrigel and their lids were placed at RT for 1 h. Cells were plated onto chambered slides 
by dissociating to single cells with Accutase (Invitrogen) using two-step approach 
described earlier in part 2.2., centrifuged, and resuspended pellet in X-Vivo media with 
ROCK inhibitor (2 µM Thiazovivin). Cells were maintained for a minimum of 3 weeks until 
a confluency of 100%, and hexagonal morphology had been reached and then prepared 
for fixation. Cells were fixed by adding 4% Paraformaldehyde (PFA) in PBS, and incubated 
at 4 0C for 30 min. Then they were washed twice with cold 1 x PBS and blocked with 5% 
horse serum, 2% goat serum, 3% BSA + 0.3% Triton X-100 in PBS at RT for 1 h. Slides 
were immunostained with N-Cadherin (ThermoFisher, mouse; 1:200), MITF 
(ThermoFisher, mouse; 1:100), ZO-1 (ThermoFisher; Rabbit; 1:300) in 
immunofluorescence buffer (5% horse serum, 2% Goat serum, 3% BSA + 0.1% Triton X-
26 
 
100 in 1 x PBS) and incubated overnight at 4 0C. Next day, wells were washed 3 x with 1 
x PBS, and stained with corresponding secondary antibody (Alexa FluorR 488 - Mouse 
1:500; Alexa FluorR 555 - Rabbit, 1:500, ThermoFisher) and maintained in the dark for 2 
h. Samples were subsequently washed and counterstained with Hoechst (DNA stain) for 
10 min. Coverslips were mounted with ProLong Gold mounting medium (Invitrogen). 
 
2.7. Recombinant Adeno-associated virus (rAAV) production 
rAAV.CMV.CbA.eGFP serotypes panel. The enhanced green fluorescent protein 
(eGFP)-encoding cDNA was cloned under the control of the CMV enhancer, chicken beta-
actin promoter plus a portion of the chicken beta-actin intron into the pAAV backbone 
plasmids. A panel of different rAAVs with 11 different capsid serotypes including AAV1, 
AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV7m8, AAV8, AAV8b, AAV9 was generated 
for use in in vitro and in vivo studies. Basically, AAV vector were generated by triple 
transfection into HEK293T cells and purified using CsCl at the Center for Advanced 
Retinal and Ocular Therapeutic (CAROT)’s AAV Vector Core. Silver staining as used for 
titration of each rAAV vector. Vectors were stored with 0.001% Pluronic F-68 at -80°C until 
just prior to use. 
rAAV.CMV.CbA.hCHM. The human CHM cDNA was cloned under the control of 
the same CMV-CβA regulatory sequence used to drive eGFP (previously described) using 
AAV serotype 7m8 vector. Based on the titer of the rAAV vector and the cell number of 
treated samples, AAV7m8.hCHM was diluted to a dosage of 1E5 vector genome (vg)/cell 
for gene augmentation studies in iPSC-RPEs.  
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2.8. In Vitro Transduction efficiency mediated by different recombinant AAV 
serotypes 
Wells were treated with 1E5 vg/cell of each rAAV serotypes. At designated time 
points after infection (24 h, 48 h, 72 h, 96 h), plates were imaged quantitatively for eGFP 
using a Typhoon 9400 Variable Mode Imager (GE Healthcare) with a 520BP40 emission 
filter and a 488-excitation filter, with the photomultiplier set at 570 V, the sensitivity set at 
normal and the focal plane to +3 mm. Images were analyzed for densitometry using 
ImageJ31 and the Protein Array Analyzer plugin. Wells were normalized to negative 
controls lacking viral vectors. Samples were run in triplicate and run in three independent 
experiments.  
 
2.9. Transduction efficiency of different rAAV serotypes in Non-Human Primates 
(NHPs) 
The studies were performed in compliance with federal and institutional mandates. 
Adult normal-sighted cynomolgous macaques were housed and cared for at the animal 
facility at The Children’s Hospital of Philadelphia (CHOP, Philadelphia, PA) under IACUC 
protocol #1061. Subretinal injections of AAV in NHPs were carried out under coaxial 
illumination through the operating microscope and after administering anesthesia as 
described (Ramachandran et al., 2017). NHPs were euthanized one month post-injection. 
Tissue was fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS), 
cryoprotected in 30% sucrose overnight at 4 0C, and then embedded and cryosectioned 
(12 µm) when frozen in optimal cutting temperature media (Fisher Scientific Co., Pittsburg, 
PA, USA) on a Leica CM1850 cryostat (Leica Microsystems, Wetzlar, Germany) as 
previously published (Ramachandran et al., 2017). Sections were evaluated for direct 
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eGFP fluorescence after mounting sections with DAPI (4’,6-diamidino-2-phenylindole) in 
Fluoromount-G (Southern Biotech, Birmingham, AL). To confirm the complete absence of 
eGFP in the sections that direct eGFP fluorescence was undetectable, immunofluorescent 
detection of eGFP using anti-eGFP primary antibodies (Molecular probes A11122; Life 
Technologies) at 1:200 dilution followed by Alexa FluorR 488 secondary antibodies at 
1:200 dilution (Life Technologies) was carried out. After staining, slides were observed 
under a confocal laser-scanning microscope (Olympus Fluoview 1000). 
 
2.10. Prenylation assay  
RPE cultures were maintained on tissue culture dishes for a minimum of 2 months 
to establish a hexagonal morphology prior to analysis. iPSC-RPE cells were either 
untreated or transduced with AAV7m8.hCHM viral vectors at the multiplicity of infection 
(MOI) of 1E5 viral genome (vg)/cell. Cells were maintained in culture media for 3 weeks 
post-transduction, then washed with cold PBS and scraped to collect a cell pellet. Cell 
pellets were lysed using prenylation lysis buffer (25 mM HEPES pH 7.2, 40 mM NaCl, 2 
mM DTE, 2 mM MgCl2, 20 µM GDP, 10 µM ZnCl2) with protease inhibitor cocktail. Cell 
lysates were cleared by centrifugation. The cytosolic fraction of the cell lysate was 
collected by ultracentrifugation at 100,000g at 4 0C for 1 h. Cytosolic fractions were used 
to perform in vitro prenylation activity. An in vitro prenylation assay was performed using 
[3H]-geranylgeranyl pyrophosphate (GGPP) as a prenyl group donor, in presence of 
recombinant Rab geranylgeranyl transferase and Rab27 (custom order from Blue Sky 
Biotech, Worcester, MA) as described (Black et al., 2014; Vasireddy et al., 2013). 
Incorporation of radiolabeled prenyl groups into the Rab27 protein was measured by liquid 
scintillation analyzer (Tri-CarbR 4810 TR, PerkinElmer). Prenylation reactions were 
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performed in iPSC- RPE from unaffected controls, CHM and AAV7m8.hCHM transduced 
cell lines.  
 
2.11. Phagocytosis Assays 
pHrodo™ Escherichia coli BioParticles® conjugate were purchased through 
Invitrogen, Carlsbad, CA. iPSCs grown on 8-well chambers were maintained until all 
monolayer cultures had a cobblestone appearance (approximately 3-4 weeks post-
passaging). iPSC-RPEs were incubated with 300 µL of pHrodo™ BioParticles® conjugate 
(1 mg/mL) for 2h at 37 0C; thereafter, the cultures were washed 3 x with 1 x PBS to remove 
any residual pHrodo bioparticles (designated as 0h). RPE at 4, 8, and 24 h time points 
were fixed with 4% PFA for 15 min at room temperature, then washed 3 x with PBS. After 
washes, cultures were stained with Hoechst (1:2000, nuclear stain), washed and mounted 
using Prolong Gold mounting medium (Invitrogen) and imaged on an inverted microscope 
(Leica DI8; Leica instruments, Inc.). Mean fluorescent units were measured per cell for 
each time point in triplicate. 
  
2.12. Statistical Analysis 
Data from each experiment were collected from three unaffected individuals 
(controls) and 3 CHM donors. Statistical results are described as the mean value ± 
standard error of the mean (SEM). The statistical significance was determined using 
Student’s T-test (between averaged control and CHM). Statistics were considered 
significant with a p-value <0.05. Asterisk corresponding to the p-value (*p <0.05, **p <0.01, 
***p < 0.001). 
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For transduction efficiency comparison between 11 AAV serotypes in iPSC and 
iPSC-RPE, ANOVA with two factors (Excel’s analysis toolpak) with replication to 
determine the relationship of cell lines and AAV serotypes on the gene expression effect 
(significance with p-value < 0.05, F > Fcritical). To determine the significant effect of each 
AAV serotypes for each cell line, ANOVA with one factor was used, followed by the post-
hoc test pair-wise comparison (XLSTAT add-ins) to determine the statistical differences 
of AAV-eGFP intensity across AAV serotypes and cell line type. 
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CHAPTER 3 – PRODUCTION OF CHM PATIENT DERIVED IN VITRO CELLULAR 
MODELS 
 
 
Overview 
To overcome the limitations and lack of availability of animal models of choroideremia, we 
utilized personalized in vitro cellular models and hypothesized that patient-derived cell 
lines exhibit pathophysiologic and biochemical characteristics of the CHM disease. In this 
chapter, we generated in vitro cellular models for choroideremia - induced pluripotent stem 
cells (iPSCs) from primary peripheral blood mononuclear cells (PBMCs) of different 
individuals with choroideremia and differentiate those iPSCs into an ocular cell type - 
Retinal Pigment Epithelium (iPSC-RPE) for further investigation.  
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Introduction 
Choroideremia (CHM) is an X-linked disorder with an incidence of approximately 
1:50,000 (MacDonald et al., 2009). CHM is a progressive retinal degenerative disease 
that is characterized by childhood-onset night blindness (nyctalopia), loss of peripheral 
vision, and progressive loss of neural retina, RPE and choroid in a peripheral-to-central 
fashion. The cone photoreceptor-enriched region of fine visual discrimination, the fovea, 
is spared until late in the disease, but ultimately, total blindness results from destruction 
of this area, typically after the fifth decade of life (Aleman et al., 2017; Sanchez-Alcudia et 
al., 2016). The disease-causing gene, CHM, encodes Rab Escort Protein-1 (REP1), a 
protein that enhances geranylgeranylation of ras-related GTPases, Rab proteins. The 
precise mechanisms by which lack of REP-1 in the retina leads to disease are unknown, 
however a lack of prenylation of specific Rab proteins (Rab27a, Rab6a, Rab38) leads to 
defects in trafficking of motile small vesicles which is implicated in the disease pathogenies 
of CHM (Bolasco et al., 2011; Köhnke et al., 2013). To date, more than 110 mutations 
have been found to result in CHM. In extra-ocular tissues, REP2 compensates for a lack 
of REP1 and so disease is limited to the retina (Köhnke et al., 2013; Larijani et al., 2003). 
The primary retinal cell type leading to choroideremia is unknown, although 
evidence from engineered mice and zebrafish and cells from affected individuals indicate 
that the affected cells are likely involve RPE cells, photoreceptors or potential choroidal 
cells (Anand et al., 2003; Black et al., 2014; Cereso et al., 2014; Tolmachova et al., 2013, 
2012; Vasireddy et al., 2013). Studies of CHM in mouse models are challenging in large 
part due to the fact that lack of Rep-1 is lethal in utero in this species. Use of conditional 
mutants has helped confirm that RPE and photoreceptor cells are likely primary cell types 
causing the disease although these animals are not faithful models of the disease and are 
also difficult to access. Further, the fact that the earliest symptoms of Choroideremia in 
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humans include nyctalopia and loss of peripheral visual fields together with the 
preservation of cone photoreceptor (foveal) function until late in the disease (Aleman et 
al., 2017) suggest that rod (but not cone) photoreceptors are affected early in the disease 
course. Because of the difficulties with in vivo models for Choroideremia and other retinal 
diseases, we and others have explored the approach of using pluripotent stem cell (iPSCs) 
models (Cereso et al., 2014; David A Parfitt et al., 2016; Vasireddy et al., 2013).  
Retinal pigmented epithelial cells are a critical cell type for active investigations for 
retinal developmental models, cell transplantation, and are increasingly used for 
preclinical assessment of therapeutics (Bennett, 2017; Kamao et al., 2014). RPE are a 
thin layer of pigmented epithelium that are adjacent to the photoreceptors of the retina and 
the Bruch’s membrane. The RPE monolayer provides numerous functions in the retina, 
such as protection against photo-oxidative stress, provision of nutrients (including 
secretion of growth factors and cytokines), maintenance of separation from the blood 
supply (in part due to integrity of apical and basal polarity) and removal of waste products 
(due in part to elimination of outer segments of photoreceptors through phagocytosis) 
(Gordiyenko et al., 2010; Sun et al., 2016). 
In this study, we explored the utility of iPSC-RPE to study disease pathogenesis 
and a potential gene-based intervention in four different genetically distinct forms of CHM 
which together, represent the most common disease-causing mutations: splicing defects, 
deletions and premature stop signals. First step was to generate iPSCs from peripheral 
blood mononuclear cells (PBMCs) of four CHM patients. Cells from normal-sighted 
individuals were used as control. Pluripotency markers expression and differentiation 
capability into three germ layers were characterized in those iPSC lines. The next step 
was to differentiate these iPSC lines into Retinal Pigment Epithelium (RPE) using a series 
of retinal inducing factors (Noggin, DKK1, IGF1, and bFGF) and other factors 
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(Nicotinamide, Activin A, SU5402, and vasoactive intestinal peptide [VIP]) at appropriate 
time points (Buchholz et al., 2009; Uchholz et al., 2013). iPSC-RPEs were characterized 
by their morphology, physiological features (RPE markers expression, tight junction, 
polarization, and phagocytosis). iPSC-RPEs from CHM patients were confirmed to lack of 
REP1 expression and their pathophysiological features were characterized in the 
subsequent chapter.  
Results 
Development of human in vitro model of CHM using patient derived samples. 
To investigate the impact of CHM mutations in a human biological system, we 
generated patient derived induced pluripotent stem cells from four CHM individuals. The 
role of REP1 has been studied in fibroblasts, blood, and RPEs (Cereso et al., 2014; 
Gordiyenko et al., 2010; Tolmachova et al., 2013). Previous in vitro studies have 
demonstrated that REP1 is involved in protein prenylation and trafficking of Rab proteins. 
Rab proteins are a family of small GTPases involved in vesicular trafficking. Post-
translational geranylgeranylation of these Rab proteins is crucial for their membrane 
association and function. Transfer of the geranylgeranyl (prenyl) groups to the Rabs by a 
transferase requires an accessory component, REP1. Lack of REP1 in CHM affects the 
transfer of prenyl groups affecting the prenylation and trafficking of Rab proteins. Our 
preclinical proof of concept studies using AAV vectors delivering REP1 have shown the 
restoration of REP1 mediated Rab27a protein trafficking and prenylation in fibroblasts and 
iPSC derived from patients with CHM mutations (Black et al., 2014; Vasireddy et al., 2013). 
However, the role of CHM mutations in patient derived ocular cells such as retinal 
pigmented epithelium RPE, has not been extensively studied. To generate a model to 
study prenylation, phagocytosis, and Rab27a protein localization and trafficking 
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underlying ocular phenotypes in CHM, we established iPSCs using Sendai 
reprogramming methods (Maguire et al., 2015). Peripheral blood was obtained from four 
patients to generate iPSC representative of their CHM phenotypes. These cell lines were 
designated as CHM-1, CHM-2, CHM-3, CHM-4. Each cell line showed normal iPSC 
morphology and molecular genetic analysis confirmed that cells harbor mutations in the 
CHM gene (Figure 1A-B). Pluripotency surface (SSEA3/SSEA4) and gene expression 
marker show high expression in CHM and control iPSC (Figure 1C-D). The removal of 
transgene from Sendai virus vector was confirmed (Figure 1E). In addition, all cells studied 
were karyotypically normal over > 20 passages, and in vitro differentiation germ layer 
assay confirmed competency to generate mesoderm, endodermal and ectodermal lineage 
specific gene expression (Figure 1F-G). Upon confirmation of cellular defects in iPSC, we 
investigated the capacity of these patient cell derived cell lines to generate retinal 
pigmented epithelium in vitro.  
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Figure 2. Analysis of iPSCs generated from patients with Choroideremia (CHM) 
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(A) Morphology of control and CHM-iPSC colonies. (B) Mutational analysis of affected 
donors: CHM1 (Ex10 c.1327_1328delAT), CHM2 and CHM3 have exon 2-4 deletions, 
and CHM4 (Ex14 Arg555STOP AGA->TGA). (C) Representative flow cytometry 
analysis plots of undifferentiated markers in control and CHM iPSCs: SSEA3/SSEA4. 
(D) Quantitative PCR (qRT-PCR) of relative gene expression of key pluripotency genes 
compared to control iPSC. (E) Transgene deficient iPSC lines shown by loss of Sendai 
genome. (F) Normal karyotyping of all four CHM iPSC lines. (G) qRT-PCR germ layer 
assay demonstrating efficient ectodermal (ECTO), mesodermal (MESO) and 
endodermal (ENDO) lineage-specific gene expression in CHM-iPS cell lines under 
induction conditions.  
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Generation of ocular specific cell type for modeling CHM in vitro. 
Choroideremia patients exhibit progressive retinal degeneration leading to RPE 
atrophy and loss of peripheral vision throughout life. In order to develop a model amenable 
to studying the disease pathology of RPE development and maintenance, we investigated 
the capacity of CHM-iPSCs to generate monolayer cultures of RPEs. This was performed 
using a semi-confluent monolayer differentiation protocol which involves the addition of 
retinal inducing factors (DKK1, Noggin, Nicotinamide, Activin A, bFGF, VIP, SU5402 and 
IGF1) at specific time points to induce formation of RPE cultures as previously described 
(Buchholz et al., 2009; Uchholz et al., 2013). After 35-day post-induction, cells were 
passaged onto fresh matrigel-coated dishes and expanded to enrich RPE population. At 
passage 1, cells were plated onto matrigel-coated culture dishes and 8-well glass slides. 
After 3-4 weeks, cultures from three of the donors, CHM-1, CHM-2, and CHM-3, exhibited 
a similar “cobblestone” epithelial appearance on a phase contrast microscope, and protein 
expression of adherens junction marker (N-Cadherin and Zo-1), and RPE specific markers 
(OTX2 and MITF) (Figure 2A). Cells from the fourth donor, CHM-4, generated very few 
RPE cells after multiple tries, so they were not used for further iPSC-RPE experiments. 
Additional markers were evaluated in the CHM-1, CHM-2 and CHM-3-derived RPEs using 
qRT-PCR that showed high gene expression of key RPE markers; MITF, BEST1, Pmel17, 
TYR, and N-cadherin (Figure 2B). To verify cellular phenotype of CHM-derived RPE, we 
measured REP1 protein expression of control and CHM-RPEs and our analysis showed 
no expression in CHM-derived RPEs (Figure 2C).  
To study polarized RPE cultures, we transferred control and CHM-RPEs to 
fibronectin coated transwell membranes and after 4 weeks of expansion all cultures 
exhibited morphologically identical hexagonal appearance. As establishment of tight 
junctions is a key element of the epithelial integrity of RPE, so we measured the 
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transepithelial electrical resistance (TER) across the monolayer of RPE grown on 
transwells. All control and CHM-RPEs demonstrated a transepithelial electrical resistance 
(TER; Ω cm2) of greater than 250 Ω cm2 (data not shown). Additionally, secretion of 
Vascular Endothelial Growth Factor (VEGF) and pigment epithelium derived factor (PEDF) 
was correctly localized to basal or apical aspects, respectively (Figure 2D). These data 
confirmed the establishment of an efficient and reproducible retinal cell type-specific in 
vitro model for studying Choroideremia. Taken together, our data indicates that RPE 
cultures developed from CHM and control iPSC lines exhibit the typical RPE phenotypes 
and show functional characteristics of RPE cells. CHM iPSC-RPE showed biochemical 
physiological defects due to REP1 lacking including a reduction in prenylation, a decrease 
in phagocytosis, an alteration of Rab27a protein trafficking and its localization. All of those 
features were confirmed and discussed in Chapter 5.  
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Figure 3. Generation and characterization of iPSC-RPE from control and 
Choroideremia (CHM) individuals. 
(A) Representative Phase images of RPE morphology and protein expression of RPE 
markers, N-Cadherin, OTX2, and MITF/ZO-1 (green/red) in control (JBWT2, JBWT3, 
JBWT4) and choroideremia (CHM-1, CHM-2, CHM-3) iPSC-RPEs. (B) Quantitative RT-
PCR shows gene expression of key RPE markers relative to donor RPE samples. (C) 
Western blot image shows lack of REP1 protein expression in all CHM-RPEs with 
corresponding GAPDH expression. (D) Polarized RPE protein secretion of VEGF and 
PEDF in control and CHM RPEs.  
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Summary 
- 4 different CHM iPSC cell lines were generated and characterized their 
pluripotency. 
- 3 iPSC-RPE were successfully generated exhibiting RPE characteristics: 
RPE gene expression, RPE protein markers, polarization, and CHM cellular 
phenotypes of lacking REP1. 
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CHAPTER 4 – IN VITRO AND IN VIVO TRANDUCTION EFFICIENCY OF AAV 
SEROTYPES 
Overview 
In order to find suitable AAV serotypes carrying CHM gene for our gene 
augmentation therapy on our in vitro cellular models and potentially for in vivo application 
in the future, we screened the transduction efficiency of AAV serotypes 1-9 panels (11 
AAV serotypes) across various in vitro cellular models (iPSCs and RPE) and comparing 
the transduction efficiency of two best candidates (AAV5 and AAV7m8) on non-human 
primate model. 
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Introduction 
With the discovery and evolution of AAV vectors for gene therapy, research has 
been focused on creating and choosing specific AAV serotypes to be able to deliver a 
transgene efficiently into the cell type/tissue of interest. Each of those serotypes has 
different tropism characteristics in different cell types or tissues. Endocytosis of AAV 
particles corresponding with the binding with different AAV receptors on the surface of the 
specific cell types. However, a direct screening of AAV serotypes on cell type of interest 
is critical. In this study, we perform a direct screening using 11 different AAV serotypes 
(AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV7m8, AAV8, AAV8b and AAV9) 
carrying the identical reporter transgene cassette: an enhanced green-fluorescent protein 
(eGFP) gene driven by the cytomegalovirus immediate-early enhancer (eCMV) and 
chicken beta actin (CbA) promoter, which was transduced into two cellular models 
generated in Chapter 3: human iPSC, iPSC-derived RPE (Figure 4). 
 
 
Figure 4. Transduction efficiency testing on iPSC and iPSC-derived RPE. 
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Human in vitro cellular models (iPSC and iPSC-derived RPE) were generated and 
cultured in their optimal condition. Before transduction efficiency testing, cells were 
collected and seeded at equal cell number in each well of two 96-well plates which were 
coated with matrigel previously. 11 AAV serotypes at different multiplicity of infection 
(MOI) were introduced to the cells in triplicate. GFP expression was measured by 
scanning the plate in Typhoon scanner followed by an analysis with protein array 
analyzer on imageJ. The transduction efficiency was normalized with background from 
untransduced wells and used as data to compare the critical effect of cell types and 
AAV serotypes on transgene expression.  
 
 
Results 
Transduction efficiency of AAV-eGFP panel in iPSCs and iPSC-derived RPEs. 
Analysis of AAV tropism was performed on iPSCs derived from two individuals 
(JBWT2 and JBWT4), and cell lines were cultured in undifferentiated cell culture 
conditions to maintain a pluripotent state. Prior to transduction, cultures were observed for 
pluripotency cell morphological characteristics and surface markers expression (Figure 
5A). iPSC cultures were transduced with 11 different serotypes at three different MOIs of 
1E4, 1E5, and 1E6 vg/cell. The AAV-eGFP expression post-infection was recorded using 
live cell imaging using a Typhoon fluorescent plate reader at 24, 48, 72, and 96 h. The 
expression of GFP was observed to be dose and time dependent, and only at an MOI of 
1E6 were all 11 rAAV expressed to measurable levels (Figure 5B-C). AAV-eGFP 
expression was first noticeable at approximately 48 h post-transduction and the level of 
expression stayed constant throughout the 96 h of experimentation. It is important to note 
that the iPSCs after 96 h are 100% confluent resulting in spontaneous differentiation; 
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therefore, the evaluation at later time points of the pluripotent state is no longer possible. 
There were significant differences across rAAV vectors used and the iPSC transduction 
efficiencies from highest to lowest were as follows at MOI: 1E6 vg/cells: AAV3, AAV7m8, 
AAV6, AAV2, AAV8, AAV1, AAV9, AAV8b, AAV4, AAV7, and AAV5 (Table 3). The group 
of higher transduction efficiency starts from AAV3, AAV7m8, AAV6 and AAV2 (» 3 to 5 
folds higher than the low transduction efficiency group). The transduction with AAV7m8 
was the only serotype to be expressed across all vector dosages (1E4, 1E5, and 1E6 
vg/cell). The AAV-eGFP expression using AAV3 and AAV6 were the only other rAAVs to 
be expressed at more than one dosage (1E5 and 1E6 vg/cell). Identifying the appropriate 
AAV vector for gene delivery in pluripotent stem cells (PSCs) is important and expanding 
our repertoire of tools is essential. Previous work has investigated the use of AAV1, AAV2, 
AAV6, and AAV9 for transduction of PSC and demonstrated that AAV2 and AAV6 have 
the greatest tropism for pluripotent stem cells (Rapti et al., 2015). Our work supports these 
findings, and shows that AAV3 and AAV7m8 substantially increase transgene delivery 
and expression in additional serotypes for gene therapy of iPSCs. Moreover, the 
differentiation of pluripotent stem cells to ocular cells types are of profound significance 
as these areas are prime targets for gene augmentation strategies for therapeutic 
intervention.  
RPE cells have been subject to a number of clinical interventions for the treatment 
of disorders associated with vision impairments such as retinitis pigmentosa (RP), Leber’s 
congenital amaurosis (LCA), advanced neovascular age-related macular degeneration 
and choroidal neovascularization (Ghazi et al., 2016; Heier et al., 2017; MacLaren et al., 
2014; Schnabolk et al., 2018). The differentiation of iPSCs to retinal pigmented epithelium 
(RPE) cells provide for structurally and functionally valuable tools for genetic and 
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therapeutic studies (Blenkinsop et al., 2015; Cereso et al., 2014; Vugler et al., 2008). Here, 
we expand the list of rAAV serotypes available for in vitro transduction of human iPSC-
RPEs (Figure 5D). Similar to iPSCs, there were time, dosage and vector effects observed 
in iPSC-RPEs with and administration of 1E6 vg/cell. We identified 1E6 to be the only 
dosage with detectable AAV-eGFP expression among all rAAV serotypes (Figure 5E). 
AAV-eGFP fluorescence did not appear until 48 h similar to iPSCs; however, there was a 
time- dependent expression effect with maximal fluorescence intensity per cell being 
reached at 96 h post-transduction. RPE were able to be maintained on culture dishes for 
months post-transduction and eGFP expression was also maintained; moreover, the level 
of transgene expression remained consistent with expression measured at 96 h post-
transduction (data not shown). In the majority of the rAAV serotypes administered, there 
was noticeable AAV-eGFP expression at the lowest MOI (1E4 vg/cell), but expression was 
increased by more than ~3-fold (1E5 vg/cell) and ~7-fold (1E6 vg/cell) at the higher MOIs 
across most rAAVs (Figure 5F). The increases in intensity or AAV-eGFP expression is not 
directly associated to the vector copy number increase (10 and 100 x, respectively), which 
could reflect a threshold for AAV endocytosis and processing of the capsids presented to 
RPE cells.  A pattern of transduction efficiencies was observed in RPEs from highest to 
lowest were as follows at MOI: 1E6 vg/cells: AAV6, AAV7m8, AAV4, AAV3, AAV5, AAV1, 
AAV2, AAV8, AAV8b, AAV7, and AAV9 (Table 3). The higher transduction efficiency 
group includes AAV6, AAV7m8, AAV4, AAV3, AAV5, AAV1, AAV2 (~ 2 to 5 folds higher 
compare to other serotypes). In vitro screening has given a list of best candidates for our 
gene augmentation on iPSC-RPEs. Studying their performance in vivo is the next 
important step to decide which serotype is the best for CHM gene augmentation 
therapeutic intervention.  
 
47 
 
 
Figure 5. iPSC and iPSC-RPE tropism of 11 rAAV serotypes. 
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(A) Representative morphological and surface marker expression (SSEA3 and SSEA4) 
of pluripotent stem cells. (B) The onset of GFP expression in iPSCs at a dosage of 1E6 
vg/cell for all rAAV at 48, 72, and 96 h post-transduction. (C) Heatmap showing relative 
AAV-GFP expression per cell across all rAAV, dosages, and time in iPSCs. The scale 
bar shows the intensity of AAV-eGFP expression presented as an arbitrary relative 
fluorescence unit (A.U) per cell. (D) Retinal pigmented epithelium (RPE) show 
“cobblestone” appearance with expression of ZO-1 (red) and MITF (green), and merged 
images showing uniform RPE monolayer.  Images were captured at 20x magnification.  
(E) AAV-eGFP expression in RPEs at a dosage of 1E6 vg/cell for all rAAV at 48, 72, 
and 96 h post-transduction (F) Heatmap showing relative AAV-eGFP expression per 
cell across all rAAV, dosages, and time in RPE cells.     
 
Non-human primate AAV5 and AAV7m8 transduction 
We set out to determine which one of two rAAVs, AAV5 (previously noted to be 
the most efficient vector in vitro iPSC derived-RPEs studies by Cereso et al. (Cereso et 
al., 2014) and also ranking highly in our studies) and AAV7m8, created through 
evolutionary design (Dalkara and Byrne, 2013) and even more efficient than rAAV5 in our 
in vitro screen, might be most useful ultimately in human clinical trials (Figure 6A). To do 
this, we compared transduction efficiencies of AAV7m8 and AAV5 as a function of dose 
after subretinal injection in the non-human primate (NHP) retina. Since only primates 
(including humans) have a macula, a region of fine visual discrimination, NHPs seemed 
to be the most appropriate model. The goal was to identify the vector that was most 
efficient in targeting both rod photoreceptors and RPE cells as evidenced by expression 
of a CMV/CβA -driven reporter gene (eGFP) delivered by the AAV. 
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Transduction efficiencies of AAV5 vs AAV7m8.CMV.CβA.eGFP were compared in 
cynomolgous monkeys after subretinal injection of 1E10, 1E11, or 1E12 vector genomes 
(vg) and samples collected one month post-injection. As shown in Figure 6B, transduction 
of photoreceptors (occupying the outer nuclear, outer synaptic and outer segment layers), 
and RPE cells is far more efficient using AAV7m8 compared to AAV5. Further, rod 
photoreceptors are transduced efficiently with AAV7m8 but not AAV5. The latter mostly 
transduces cone photoreceptors (and only at doses >1E11 vg). AAV7m8 transduces rod 
(but not cone) photoreceptors at 1E10 vg, but both rods and cones at 1E11vg and higher. 
Thus, results from both the in vitro screen and from in vivo studies supported focusing 
further evaluations using AAV7m8. 
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Figure 6. Transduction efficiency of recombinant AAV vectors A) in vitro and B) 
in vivo in the non-human primate (NHP) retina. 
A) Transduction efficiency of iPSC-derived RPE cells generated from normal-sighted 
males (JBWT2 and JBWT4) using two rAAVs (AAV5 and AAV7m8) at an MOI of 1E5 
vg/cell and all containing a chicken β actin (CBA) promoter with cytomegalovirus (CMV) 
enhancer driving enhanced green fluorescent protein (eGFP) cDNA. rAAVs delivered to 
cells were evaluated for intensity of eGFP at 4 different time points (24, 48, 72, and 96 
51 
 
hrs) post transduction. B) Comparative cellular transduction efficiencies in NHP retinas 
after subretinal delivery of AAV5 vs AAV7m8.CMV/CβA.eGFP over a dose range from 
1E10 – 1E12 vector genomes (vg). Direct fluorescence of eGFP was evaluated 
histologically one month after injection. RPE, retinal pigmented epithelium; OS, outer 
segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear 
layer; GCL, ganglion cell layer. Scale bars represent 40um. 
 
 
 
 
 
 
 
 
 
Summary 
- For iPSC: We identified high in vitro transduction efficiency group (AAV3, 
AAV7m8, AAV6 and AAV2), and low in vitro transduction efficiency group 
(AAV8, AAV1, AAV9, AAV8b, AAV4, AAV7, and AAV5). 
- For iPSC-RPEs: We identified high in vitro transduction efficiency group 
AAV6, AAV7m8, AAV4, AAV3, AAV5, AAV1, AAV2, and low in vitro 
transduction efficiency group AAV8, AAV8b, AAV7, and AAV9. 
- AAV7m8 is the best candidate for both in vitro (iPSC, and RPE) and in vivo 
(Non-human primate, target Photoreceptors and RPE) 
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CHAPTER 5 – GENE AUGMENTATION THERAPY USING AAV7m8.CMV.CβA.hCHM 
on iPSC-RPE 
 
 
 
Overview 
In this chapter, we studied the rescue effect of exogenous REP1 on iPSC-RPEs  in term 
of prenylation, phagocytosis, protein trafficking.  
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Introduction 
Current clinical studies for CHM focus on gene augmentation strategies using AAV2 
and aim to prevent further degeneration and potentially also to enhance retinal function 
(Aleman et al., 2017; Edwards et al., 2016; MacLaren et al., 2014). Progression to the 
human clinical trial reported by Aleman et al was supported by the fact that AAV2-hCHM 
rescues prenylation and Rab27a protein trafficking in undifferentiated iPSC’s derived from 
subjects with CHM mutations (Vasireddy et al., 2013). Recent clinical trials demonstrated 
the safety and efficacy of AAV2 mediated viral delivery (Edwards et al., 2016; MacLaren 
et al., 2014). In addition to delivering the transgene to RPE efficiently, high doses of AAV2 
are required to target photoreceptors in non-human primates (Vandenberghe et al., 2011). 
In the present study, we further investigated the role of CHM mutations on cellular 
trafficking, phagocytosis, and RAB27a localization in patient-derived iPSCs differentiated 
into RPEs. We show that lack of REP1 leads to reduced and delayed phagocytosis, 
perinuclear accumulation of Rab27a, and inhibition of prenylation in three CHM patient-
derived iPSC-RPEs. These defects are rescued by gene augmentation through the 
delivery with a vector that could be used in the future to deliver the transgene efficiently to 
the likely primary disease-causing cells, photoreceptors and RPE cells, in humans, 
AAV7m8-CHM. 
 
Results 
Adeno-associated viral delivery of hCHM cDNA rescues prenylation defect in iPSC-
RPE.  
The effect of mutations in the CHM gene on prenylation of Rab proteins in human 
iPSC-derived RPE was examined using an in vitro prenylation assay as previously 
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described (Köhnke et al., 2013; Vasireddy et al., 2013). This assay was developed to 
measure unprenylated Rabs in cell lysates, which had accumulated in RPE derived from 
CHM iPSC. To examine the AAV-mediated gene augmentation of REP1 in CHM-RPEs, 
we used CMV/CBA-hCHM vector packaged into AAV7m8 capsids. This was administered 
to the RPE cultures at 1E5 vg/cell (AAV7m8-hCHM). Transduced cultures were 
maintained for a minimum of 3 week prior to analysis and showed no change in 
morphology compared to untransduced CHM or control iPSC-RPEs. After ~3 weeks of 
treatment, RPE were collected and analyzed for REP1 protein content and the degree of 
prenylation in control, CHM, and AAV7m8-hCHM CHM-RPE. REP1 was present in the 
control samples (JBWT2, JBWT3, JBWT4) and absent in untreated CHM-RPE (CHM1, 
CHM2, CHM3); however, after CHM-RPE cultures were transduced with AAV7m8-hCHM, 
REP1 levels in CHM cells were comparable to those in controls (Figure 7A-B). To 
determine the level of unprenylated Rabs in RPE cultures, cell lysates were harvested and 
the cytosolic fractions were collected by ultracentrifugation and used for the in vitro 
prenylation assay. Using 3H-GGPP as the source of prenyl groups and cell lysate as the 
source of REP1, prenylation assays was carried out using incorporation of tritium-labeled 
GGPP as the read-out. As shown in Figure 7C, prenylation of RAB27 is significantly 
increased in AAV7m8-hCHM treated CHM-1, 2, 3 iPSC-RPE (~ 2-3 folds increase) 
compared to untreated control cells. The prenylation activity observed in AAV7m8.hCHM 
transduced iPSC-RPE is also found to be similar to the prenylation activity observed in 
unaffected controls (Figure 7D, ***p < 0.001). Thus, normal prenylation activity was 
present in three unaffected controls, and through gene augmentation using AAV7m8-
hCHM we could rescue the prenylation defects observed in all three untreated CHM-RPE 
cell lines. To gain further insight into how loss of REP1 influences a key physiologic feature 
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of RPE, we investigated the capacity of these cells to digest pHRodo bioparticles during 
phagocytoisis. 
 
Figure 7. Effects of AAV7m8-REP1 gene augmentation on REP1 protein 
expression level and cellular prenylation. 
(A) REP1 protein content in RPEs of three unaffected controls, three CHM individuals, 
and AAV7m8-REP1 (1E5 vg/cell) treated cultures. (B) Quantification of REP1 protein 
level compared to GAPDH. (C) Tritium prenylation assay shows lack of prenylation of 
Rab27a in CHM patient-derived RPEs (CHM1, CHM2, CHM3) and rescue after 1E5 
vg/cell transduction of AAV7m8-hCHM viral vector. (D) Quantitative analysis of 
prenylation in control, CHM-REP1 deficient, and AAV7m8-hCHM treated RPEs.   
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Phagocytosis is impaired in CHM-derived RPEs.  
Human and zebrafish models lacking REP1 show altered phagocyotosis. Further, 
shRNA silencing of normal REP1 expression in cultured cells has been reported to result 
in reduced phagocytosis activity (Gordiyenko et al., 2010; Koenekoop, 2007; Strunnikova 
et al., 2009). To investigate the phagocytosis and phagolysosomal activity of CHM patient-
derived RPEs, we measured the ingestion of pHrodo Escherichia coli BioParticles 
(Invitrogen, Carlsbad, CA) through fluorescence of pHrhodo dye phagocytized bioparticles 
in our confluent monolayer cultures. The bioparticle fluorescence increases as the pH of 
the surroundings becomes acidic within the lysosome. After an initial 2h of exposure, the 
pHRodo particles were extensively washed from cultures and cells were incubated for an 
additional 4, 8, and 24h. The phagolysosomal activation was greatest after 4h of exposure 
to pHRodo particles and then declined over the 24 hours post exposure. The confluent 
iPSC-RPE monolayers showed a noticeable suppression of phagolysosome activation in 
CHM patient-derived RPE cultures when compared to the control (Figure 8A). To test 
whether gene augmentation of REP1 could rescue the phagolysosomal defect, we 
transduced CHM iPSC-RPEs with 1E5 vg/cell of AAV7m8-hCHM. All CHM patient 
samples treated with AAV7m8-hCHM had significant improvement in phagolysosomal 
activity compared to matched untreated CHM patient-derived RPE cultures at 4 and 8h 
after phRodo administration (Figure 8B, **p <0.01). These results demonstrate a 
suppression in RPE ingestion and phagolysosomal activation in CHM-derived RPEs, 
which can be rescued by AAV-mediated gene augmentation.  The reduced phagocytosis 
has been suggested to involve the proper localization and action of prenylated Rab27a, 
which is necessary for vesicular transport which is disrupted by loss of REP1 in CHM.   
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Figure 8. Effects of AAV7m8-REP1 gene augmentation on phagocytosis 
activation. 
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(A) Representative phase/pHRodo and Dapi/pHRodo images of control, CHM, and 
AAV7m8-treated CHM RPE show the ingestion of phRodo bioparticles in confluent RPE 
monolayers. (B) The relative fluorescent intensity was calculated for each culture after 
4, 8, and 24h of exposure to pHRodo bioparticles  
 
REP1 is required for the prenylation and cytosolic trafficking of Rab27a in human 
RPEs.  
In view of our reported irregular distribution of Rab27a in CHM-IPSCs (Vasireddy 
et al., 2013), we directly assessed whether the distribution of Rab27a in pluripotency can 
be observed in multiple CHM patient-derived RPEs. The images presented in Figure 9A 
are representative of 4 separate cultures from each individual.  We show that control RPEs 
(JBWT2, JBWT3, JBWT4) had detectable Rab27a that was dispersed throughout the 
cytosol of RPE cells. CHM patient-derived RPEs (CHM-1, CHM-2, CHM-3) had an 
average of 71% of cells with a dispersed cytosolic distribution, and the 29% cells had 
Rab27a that was found in the perinuclear region of the cell. The distribution across 
individual cells, perinuclear versus cytosolic, is shown in Figure 9B. We next determined 
whether overexpression of REP1 using AAV7m8-hCHM could result in recovery of the 
normal (pan-cellular) distribution of Rab27a. In the majority (81%) of the >150 cells 
analyzed per culture, Rab27a was dispersed throughout the cytoplasm after treatment 
with AAV7m8-hCHM similarly to that seen in WT control RPEs. Quantification of Rab27a 
biodistribution in untreated vs and AAV7m8-hCHM CHM RPEs shows that a significant 
proportion of REP1-positive cells have a cytosolic distribution compared to untreated 
REP1-negative CHM-RPEs (Figure 9B, *p <0.05). Thus, this experiment directly 
demonstrates that prenylation of Rab27a by REP1 is required for vesicular trafficking and 
cytosolic distribution.  
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Figure 9. Mutations in CHM disrupt the localization of Rab27a and alter the onset 
of transgene expression mediated by AAV7m8 in wildtype (WT) vs mutant (CHM) 
human RPEs. 
(A) Immunostaining for Rab27a protein localization (B) Rab27a localization is presented 
in a bar graph for perinuclear versus cytosolic distribution. 
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Internalization of AAV7m8 is reduced in CHM RPEs  
A lack of REP1 in iPSC-RPE models alters the onset of transgene expression after 
transduction with AAV7m8-GFP. iPSC-RPE cells from normal-sighted individuals (JBWT2 
and JBWT3) and from individuals with CHM (CHM-1 and CHM-2) were transduced with 
AAV7m8.CMV/CβA.eGFP at an MOI of 1E5vg/cell and onset and levels of GFP protein 
were imaged as a function of time after transduction. As shown in Figure 10, GFP was 
detectable by the 24hr timepoint in all RPE cell lines, with WT controls having significantly 
more GFP expression up until 48h post-transduction compared to CHM-RPEs (***p 
<0.001). Interestingly the GFP expression was normalized between the two groups by 
72h. This data indicates that there is significant impairment in CHM-RPEs in one or more 
of the steps required in order to obtain AAV-mediated transgene expression compared to 
control RPEs.   
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Figure 10. Mutations in CHM alter the onset of transgene expression mediated by 
AAV7m8 in wildtype (WT) vs mutant (CHM) human RPEs. 
Transduction efficiency of control-RPE (JBWT2 and JBWT4) and CHM-RPEs (CHM-1 
and CHM-2) using rAAV-7m8-CMV/CBA.eGFP at an MOI of 1E5 vg/cell over a period 
of 72h.  
 
 
Summary 
AAV7m8.CMV.CβA.hCHM to choroideremia iPSC-RPEs restored normal REP1 protein 
expression, prenylation, phagocytosis, and Rab27a protein trafficking.  
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CHAPTER 6 – DISCUSSIONS AND FUTURE DIRECTIONS 
Choroideremia is an X-linked recessive monogenic disease caused by loss of 
function of REP1 protein that results in progressive degeneration of RPE, photoreceptors 
and choroid. The purpose of this study was to examine potential pathology induced by 
REP1 deficiency in retinal pigment epithelium cells of CHM patients and to investigate the 
potential for rescue using a gene augmentation strategy. There are three stages in our 
research: 1) generating iPSC and iPSC derived RPE as disease cellular models (Chapter 
3), 2) screening and choosing the best AAV serotypes for gene augmentation study 
(Chapter 4), 3) studying rescue effect of AAV7m8.hCHM on the ocular affected cell type 
of CHM (Chapter 5).  
With the limitation of CHM animal models as well as a need to find a suitable model 
to study molecular mechanism of the disease, we generated patient derived CHM cell 
lines which would be a useful resource to study the pathophysiology of CHM. In this study, 
we reprogrammed four different cell lines for peripheral blood mononuclear cells (PBMC) 
from four individuals carrying mutations in the CHM gene (nonsense, deletions, splicing 
defect). Although the cellular disease phenotype, including a decrease in prenylation and 
the mislocalization of Rab27a protein, were demonstrated in these patient derived iPSC 
models (Vasireddy et al., 2013), the specific retinal cell type affected by CHM need to be 
identified to reveal the precise role of REP1 in disease development. 
Three iPSC derived RPE cell lines were generated from three unrelated patients 
with mutations in CHM gene. CHM-1 iPSC-RPE has a deletion of two nucleotides, 
Adenine and Thymine, at the location of 1327-1328 in the CHM cDNA sequence causing 
nonsense mutation and a truncated REP1 protein (p. I460X). This mutation affects the 
63 
 
structure, stability and function of REP1 protein (Strunnikova et al., 2009). CHM-2 and 
CHM-3 iPSC-RPEs have a deletion of exons 2-4 resulting in no function of the protein 
REP1 as well. A genotype-phenotype analysis of those nonsense and deletion mutations 
showed no clear correlation in term of visual acuity, visual field, onset of symptoms 
(Freund et al., 2016). In fact, lack of functional REP1 protein is the common phenotype in 
all three patient cell lines and it was confirmed by western blot (Figure 7). 
Testing the tropism of a panel of 11 AAV-eGFP serotypes 1-9, 7m8, 8b revealed 
different patterns and fluorescent intensities of transgene expression in our in vitro cellular 
models including iPSC and RPE. This indicated that not only the rAAV serotype or the 
dosage of viral particles but also the cell type affects the level of transgene expression. 
Chapter 4 showed the transduction efficiencies listed from high to low on iPSC and RPE. 
Knowledge of the transduction efficiencies and cell tropisms is essential for selecting the 
appropriate vector to provide the required levels of transgene expression for a given 
application. In fact, having the highest level of expression will not always provide optimal 
results as the biology associated with transgene element needs to be considered. The 
endogenous level and transgene function: transcription factor, structural protein, 
chaperone, enzymes all need to be evaluated during gene augmentation testing. Our main 
focus is to select the optimal AAV serotype for in vitro gene augmentation therapy on 
iPSC-RPE and use that information to select the vector with the greatest potential for 
efficacy in vivo. AAV7m8 performs the best due to its optimal transduction efficiency in 
vitro even at low MOI (decrease dosage) as well as its infection capacity in vivo with 
respect to RPE and photoreceptors of the non-human primate model (therapeutic 
efficacy). The amount of REP1 protein produced after transduction with AAV7m8 is 1.5 
fold higher than endogenous REP1 in the wild type iPSC-RPE. Previous studies in mice 
showed that overexpression of REP1 by subretinal injection of 1E8 to 1E9 genome copies 
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of AAV2.CMV.CBA-REP1 did not cause toxicity in mice as assessed by retinal function 
(Berndt and Sebti, 2011). Flow cytometry analysis of transduced CHM iPSC-RPE with 
AAV7m8.hCHM revealed a heterogeneity of level of REP1 expression in individual cells.  
 
Figure 11. Flow cytometry analysis of REP1 in wildtype, untreated, transduced 
population of iPSC-RPE. 
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IPSC-derived RPEs have become a valuable resource for studying patient-specific 
retinal pathophysiology; therefore, we generated pluripotent stem cells from CHM-mutant 
somatic cells and then differentiated them into RPE. In previous studies, we used 
undifferentiated mutant CHM cells for study (fibroblasts and induced pluripotent stem 
cells) and showed that those cells are defective in prenylation of Rab proteins (Anand et 
al., 2003; Black et al., 2014; Vasireddy et al., 2013). Here, by differentiating patient-derived 
iPS cells into a retinal cell type, we are able to probe for other CHM-associated cellular 
phenotypes, metabolic processes (prenylation defects), and signs of cell biologic 
malfunction (suppressed phagolysosomal activation, alterations in protein trafficking).  
Efficient prenylation of Rabs (mediated by REP1) is particularly important in 
preventing vesicular trafficking defects in cells responsible for protecting against oxidative 
stress and for serving as mediators of both nutrition and waste management , roles known 
to be played by the RPE (Strunnikova et al., 2012, 2009; Zhang et al., 2015b).  Cereso et 
al. previously showed that iPSC-RPE cells display morphologic features typical of RPE 
cells (including a polarized epithelium with microvilli and desmosomes on the apical size, 
melanosomes distributed throughout the cytosol and a nucleus on the basal side), and 
that these cells express genes known to be expressed specifically in RPE cells (such as 
MERTK, RPE65, TYR) (Cereso et al., 2014). Further, these cells display many activities 
known to take place by RPE cells, such as apicobasal fluid internalization of particles 
presented to the surface of the cells. Cereso et al. also showed that CHM mutant iPSC-
RPE cells manifest a prenylation defect and that this defect can be addressed through 
AAV5-mediated delivery of a wildtype hCHM cDNA (Cereso et al., 2014). Here, we use 
iPSC-RPE cells to further probe RPE cells with CHM mutations for defects in cellular and 
physiologic functions and for the ability to correct these defects using AAV-mediated gene 
transfer. 
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The approach to track biochemical effect of lacking REP1 in the patient cell line in 
Cereso et al.’s method and our study is in vitro prenylation assay. In our 3H-GGPP radio-
labeling method, we measure the under-prenylation of exogenous Rab27a in the reaction 
with the presence or absence of endogenous REP1 protein. Cereso et al used BGPP 
(Biotin labeled BGPP) as a lipid donor to track the amount of endogenous Rab27a in the 
cytosolic fraction via estimating biotinylated Rab27a using Streptavidine horseradish 
perosidase after in vitro prenylation reaction. Overall, this in vitro prenylation assay can 
only can reveal the enzymatic activities of geranylgeranyl transferase with the support of 
REP1 in the Rab27a substrate. A more interactive method to functionally study the role of 
REP1 is an in vivo prenylation assay, through which we could determine the localization 
of unprenylated Rab in the cytosolic fraction and prenylated Rabs in the membrane 
fraction of the cells (Berndt and Sebti, 2011). In this method, it is necessary to optimize 
the method of subcellular fractionation to clearly separate cytosolic and membrane 
proteins and estimate the amount of Rabs protein in each component.  
We found that CHM-iPSC-RPEs had reduced phagocytic activity as measured by 
numbers of particles ingested over time. They also showed suppressed phagolysosomal 
activation compared to control cells or isogenically matched CHM iPSC-RPEs that were 
treated with AAV7m8-CHM. The reduced activity was found in each of the genetically 
distinct iPSC-RPE cell lines that was evaluated. This reduced phagocytic activity likely 
contributes to impaired function of both RPE cells and rod photoreceptors. The reduced 
phagocytic activity is likely a downstream effect of prenylation defects associated with loss 
of REP1. In support of this, there was a reduced ability to prenylate the substrate Rab27a 
protein in each one of the CHM iPSC-RPE cell lines. As predicted, there was no clearcut 
difference in prenylation activity in each of the mutant cell lines because each of the 
genetically distinct mutations (splice site, deletion, premature stop) likely resulted in a 
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complete lack of REP-1 protein, a protein necessary for prenylation. The fact that 
phagolysosomal activity in CHM iPSC-RPEs was present (although reduced), could 
explain why there is fairly good retinal function early in life. Light exposure and resultant 
oxidative stress together with accumulation of metabolic and protein trafficking 
dysfunctions caused by reduced phagocytosis and ability to process waste products 
efficiently likely lead to progressive RPE and photoreceptor malfunction and degeneration 
over time.  
We also found evidence of impaired intracellular protein trafficking and vesicular 
transport in the CHM-iPSC RPEs, likely also resulting from prenylation defects. This 
evidence includes the disproportionate pericellular accumulation of Rab27a in CHM-iPSC 
RPE, which was more than double that of control and AAV-treated iPSC-RPEs. Additional 
data supporting a defective trafficking was a delay in onset of rAAV-mediated GFP 
expression in CHM-RPEs compared to controls.  This could be due to inefficiency in any 
one of a host of steps starting with contact of the AAV with the cell surface receptor and 
including endocytosis. Previous studies have shown that Rab27a is an important mediator 
of endocytosis in multiple systems (Ejlerskov et al., 2012; Yamaoka et al., 2016).  
Impairment could also result in defective trafficking of the AAV to appropriate 
cellular compartments and ultimately through the nucleus pore, and then finally defective 
transformation of the single-stranded AAV DNA into the transcriptionally competent 
double-stranded DNA within the nucleus (Ejlerskov et al., 2012; Yamaoka et al., 2016). 
The good news is that the defects we observed in CHM iPSC-RPE cells can be reversed 
through efficient delivery of the wildtype hCHM cDNA. Using both iPSC-RPE cells and 
primate retina to identify an AAV serotype that most efficiently transduces the cell types 
thought to result in CHM disease, AAV7m8, we show that prenylation, phagocytic activity, 
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and protein trafficking defects could be reversed. This set of data provides further support 
for the promise of gene augmentation therapy for choroideremia. 
Localization of Rab27a is evaluated by immunocytochemistry. Another approach 
to determine the position of the protein by using flow cytometry. In this method, it is very 
critical to mask the boundary of cell compartment and the sensitivity of antibodies.  
Trafficking of other Rab proteins needs further investigation. The studies of RPE 
pigmentation and melanosome trafficking to the apical side after introducing exogenous 
REP1 is one more interesting aspect for future study. In our studies, the iPSC-RPE from 
CHM lines showed more pigmentation compared to control. Whether or not this 
accumulation of melanosome pigment is due to impaired trafficking is of future interest.   
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Table 1. Details on mutation analysis of four CHM patient cell lines. 
CHM 
cell 
line 
Patient 
annotation 
Mutation Primers Mutation 
confirmation 
via Exome 
sequencing 
CHM1 JB 415 CHM ex10 
c.1327-
1328delAT 
CHM_Ex10_F: 
TCTTAGAGCTGTGAAGGGGG 
CHM_Ex10_R: 
CTCCACCCATTAGCAAGCGA 
N/A 
CHM2 JB 500 Exon 2-4 
deletions 
N/A Yes 
CHM3 JB 527 Exon 2-4 
deletions 
N/A Yes 
CHM4 JB 588 CHM Ex14 
Arg555Stop  
(AGA à 
TAG) 
CHM-Ex14-F: 
AATAGAAGTCCAAAGGAGCATGA 
CHM_Ex14_R: 
AGGGCAAATTACAGAAATGGTAC 
N/A 
 
 
 
Table 2. Primers for iPSC, RPE characterization. 
Housekeeping GENE 
Primer 
Orientation Cat number 
  TBP Predesigned Set Applied Biosystems: Cat no. 4325803 
       
RPE 
Characterization GENE 
Primer 
Orientation IDT ID 
  Nanog Predesigned Set hs04260366_g1 
  DMNT3B Predesigned Set hs00171876_ml 
  
POU5F1 
(OCT3/4) Predesigned Set hs00999634_gh 
  cMYC Predesigned Set hs001153408_ml 
RPE 
Characterization GENE 
Primer 
Orientation Sequence 
  MITF Forward CCTGTATGCAGATGGATGATGT 
   Reverse CCGAGACAGGCAACGTATTT 
   Probe TCTTGGGCTTGATGGATCCTGCTT 
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  TYR Forward CTTACTCAGCCCAGCATCAT 
   Reverse GGGCGTTCCATTGCATAAAG 
   Probe AGCCGATTGGAGGAGTACAACAGC 
  
N-
Cadherin Forward GACAATGCCCCTCAAGTGTT 
   Reverse CCATTAAGCCGAGTGATGGT 
   Probe TCTGGAGTTTCGCAAGTCTCTGCC 
  PEDF Forward CCCAAGCTGAAGCTGAGTTAT 
   Reverse GTTTGCCTGTGATCTTGCTAAAG 
   Probe CAGGGACTTGGTGACTTCGCCTTC 
  BEST1 Forward CTCAGTGTGGACACCTGTATG 
   Reverse CCCAACTAGACAAGTCAGGAAG 
   Probe ATACACAGGTGGTGACTGTGGCG 
  PMEL17 Forward GTTGATGGCTGTGGTCCTTG 
   Reverse CAGTGACTGCTGCTATGTGG 
  
 
Probe 
AGGCGCAGACTTATGAAGCAAGAC
T 
Germ Layer 
Assay GENE 
Primer 
Orientation Sequence 
Ectoderm EMX2 Forward GCT TCT AAG GCT GGA ACA CG 
   Reverse CCA GCT TCT GCC TTT TGA AC 
   Probe 
TC AGC CTC AC GGA AAC TCA 
GGT AA 
  FOXG1 Forward GCC ACA ATC TGT CCC TCA ACA 
   Reverse CGG GTC CAG CAT CCA GTA G 
   Probe CAACAAGTGCTTCGTGAAGGTGCC 
  PAX6 Forward 
GTG TCT ACC AAC CAA TTC CAC 
AAC 
   Reverse CCC AAC ATG GAG CCA GAT G 
   Probe CCACACCGGTTTCCTCCTTCACAT 
Mesoderm GATA4 Forward GAGATGCGTCCCATCAAGAC 
   Reverse ACATCGCACTGACTGAGAAC 
   Probe CTGCTGTGCCCGTAGTGAGATGAC 
  TBX3 Forward CTTTGGGATCAGTTTCACAAGC 
   Reverse CAGCCCAGAACATCTCACTTTA  
   Probe TACCAAGTCGGGAAGGCGAATGTT 
  Hand1 Forward TGAACTCAAGAAGGCGGATG 
   Reverse GGTGCGTCCTTTAATCCTCTT 
   Probe AAACCTTCGTGCTGCTGCAGC 
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Endoderm GATA6 Forward AGACTTGCTCTGGTAATAGCAATA 
   Reverse GAGGCTGTAGGTTGTGTTGT  
   Probe TTCCCATGACTCCAACTTCCACCT 
 FOXA2 Forward CCGACTGGAGCAGCTACTAT 
  Reverse TACGTGTTCATGCCGTTCATC 
  Probe ACTCCTCCGTGAGCAACATGAACG 
 EOMES Forward CAC CGC CAC CAA ACT GAG AT 
  Reverse CGA ACA CAT TGT AGT GGG CAG 
  Probe AGCTCAAGAAAGGAAACATGCGCC 
 
Table 3. Relative fluorescence intensity (R.F.U) per cell at 96h at MOI (1E6 vg/cell) 
iPSC R.F.U SEM iPSC-RPE R.F.U SEM 
AAV3 11.01a ± 1.55 AAV6 22.86a ± 4.23 
AAV7m8 10.19a ± 1.35 AAV7m8 17.54ab ± 2.91 
AAV6 9.20a ± 0.91 AAV4 16.33abc ± 2.76 
AAV2 7.77a ± 0.78 AAV3 11.86bcd ± 1.90 
AAV8 3.18b ± 0.40 AAV5 8.82bcd ± 1.67 
AAV1 2.85b ± 0.36 AAV1 8.43bcd ± 1.51 
AAV9 2.59b ± 0.34 AAV2 7.83cd ± 1.37 
AAV8b 2.30b ± 0.30 AAV8 4.68d ± 0.95 
AAV4 1.43b ± 0.42 AAV8b 3.82d ± 0.51 
AAV7 1.28b ± 0.30 AAV7 3.66d ± 0.53 
AAV5 0.52b ± 0.18 AAV9 3.04d ± 0.55 
Pr > F(Model) < 0.0001  Pr > F(Model) < 0.0001  
*SEM: Standard error of mean 
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